Sign In
Buy SITC
$4.88
-0.0500 (-1.01%)
At Close: Jun 03, 2026
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
07:30am, Friday, 07'th Nov 2025
PHILADELPHIA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
07:30am, Friday, 07'th Nov 2025
Next generation Bria-OTS+ platform demonstrates rapid, potent and durable anti-cancer activity by activating both innate and adaptive immune responses Increased tumor cell cytotoxicity induced by both
Tetra-valent T-cell engager designed to address shortfalls of bi-specific T-cell engagers (BiTE) related to manufacturability, safety profile, and ability to treat a wide spectrum of solid tumors Tetr
Leptomeningeal metastases disease session features novel treatments in the horizon, REYOBIQ™ and ReSPECT-LM, and future directions and needs Leptomeningeal metastases disease session features novel
SITE Centers Reports Third Quarter 2025 Results
04:05pm, Wednesday, 05'th Nov 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Reports Third Quarter 2025 Results.
REIT Replay: REIT Indexes Close Final Week Of October In The Red
12:18pm, Tuesday, 04'th Nov 2025
US equity real estate investment trust indexes dropped during the final week of October. The Dow Jones Equity All REIT index closed the recent week down 3.29%, while the MSCI US REIT (RMZ) index fell
Candel Therapeutics to highlight immunotherapy advances at SITC 2025
09:54am, Tuesday, 04'th Nov 2025
Candel Therapeutics Inc (NASDAQ:CADL) will deliver three presentations at the upcoming 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC). “Candel's presentations at SITC 2025 exe
BURLINGTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Abpro Corporation (Nasdaq: ABP) (“Abpro”) and Celltrion, Inc. (“Celltrion”) today announced that they will present new preclinical data for
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients wi
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advan
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. In vivo, CTX-10726 outperforme
NEEDHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunoth
SITE Centers Announces Sale of Parker Pavilions
05:03pm, Monday, 03'rd Nov 2025
BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Sale of Parker Pavilions.
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
08:00am, Monday, 03'rd Nov 2025
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunothera
